<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148939</url>
  </required_header>
  <id_info>
    <org_study_id>Stroke</org_study_id>
    <nct_id>NCT02148939</nct_id>
  </id_info>
  <brief_title>Antiplatelet Effects in Stroke-Patients</brief_title>
  <official_title>Dipyrone Nullifies Aspirin Antiplatelet Effects in Stroke-Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients suffer from acute and chronic pain. The incidence of chronic pain correlates
      with increased age. Most of patients rely on analgesic medication to control the pain.
      Dipyrone is an extensively used drug in Western and Eastern Europe as well as Central and
      South America, largely due to its favorable analgesic and antipyretic effects in conjunction
      with a low incidence of gastrointestinal complications when compared to other non-steroidal
      anti-inflammatory drugs (NSAIDs).

      Aspirin is the backbone of antiplatelet therapy in patients after ischemic stroke. However,
      it is known that there are substantial inter-individual response variabilities to
      antiplatelet medication. Furthermore, patients with impaired response to aspirin have a
      significant higher risk of recurrent cerebrovascular events. The investigators have recently
      shown that co-medication with aspirin and dipyrone in patients with coronary artery disease
      lead to insufficient antiplatelet effects of aspirin.

      The incidence of chronic pain is very high in patients with ischemic stroke. Therefore, in
      this study the investigators aim to examine, if co-medication of aspirin and dipyrone
      interaction also occurs in patients after ischemic stroke.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory response to aspirin therapy in metamizole co-medicated Stroke patients</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events (MACCE Events) during hospital stay</measure>
    <time_frame>participants are followed until discharge up to 4 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">61</enrollment>
  <condition>Ischemic Stroke</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with ischemic stroke
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patients with ischemic stroke and ASS-medication (80-320 mg/day) with/without
             analgesic comedication

        Exclusion Criteria:

          -  Reanimation

          -  cardiogenic shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amin Polzin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Kardiologie, Pneumologie und Angiologie, Universtiätsklinikum Düsseldorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Zeus, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinik für Kardiologie, Pneumologie und Angiologie, Universtiätsklinikum Düsseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Pulmonary Disease and Vascular Medicine</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uniklinik-duesseldorf.de/kardiologie</url>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Division of Cardiology, Pulmonary Diseases, Vascular Medicine</investigator_title>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>Antiplatelet Effects</keyword>
  <keyword>aspirin</keyword>
  <keyword>metamizole</keyword>
  <keyword>dipyrone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dipyrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

